April 3 (Reuters) - ARCA Biopharma Inc :
* ARCA BIOPHARMA AND ORUKA THERAPEUTICS ANNOUNCE MERGER AGREEMENT
* ARCA BIOPHARMA AND ORUKA THERAPEUTICS ANNOUNCE MERGER AGREEMENT
* ARCA BIOPHARMA INC - UNDER TERMS OF MERGER AGREEMENT, PRE-MERGER ARCA STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 2.38% OF COMBINED COMPANY
* ARCA BIOPHARMA INC - COMBINED COMPANY PLANS TO OPERATE UNDER NAME ORUKA THERAPEUTICS, INC. AND TRADE ON NASDAQ UNDER TICKER SYMBOL "ORKA"
* ARCA BIOPHARMA INC: PRE-CLOSING PRIVATE FINANCING OF APPROXIMATELY $275 MILLION ANTICIPATED TO FUND OPERATIONS THROUGH 2027
* ARCA BIOPHARMA INC - PRE-MERGER ORUKA STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 97.62% OF COMBINED COMPANY
* ARCA BIOPHARMA INC - ARCA IS EXPECTED TO CONTRIBUTE $5 MILLION TO COMBINED ENTITY
* ARCA BIOPHARMA INC: PRE-CLOSING PRIVATE FINANCING OF APPROXIMATELY $275 MILLION ANTICIPATED TO FUND OPERATIONS THROUGH 2027
* ARCA BIOPHARMA INC - EXPECTS TO PAY A DIVIDEND TO PRE-MERGER ARCA STOCKHOLDERS OF APPROXIMATELY $20 MILLION IMMEDIATELY PRIOR TO CLOSE OF MERGER
* ARCA BIOPHARMA INC - COMBINED COMPANY WILL BE NAMED ORUKA THERAPEUTICS, INC. AND LED BY LAWRENCE KLEIN, ORUKA'S CURRENT CHIEF EXECUTIVE OFFICER
* ARCA BIOPHARMA INC: EXPECTS TO DECLARE A CASH DIVIDEND TO PRE-MERGER ARCA STOCKHOLDERS EQUAL TO AMOUNT BY WHICH ARCA'S NET CASH EXCEEDS $5 MILLION.
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。